Chemomab Therapeutics LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Touchstone Global Investments Pty Ltd has increased its beneficial ownership of Chemomab Therapeutics Ltd. American Depositary Shares to 5.2%.
NASDAQ
Erik Otto has filed a Schedule 13G, reporting beneficial ownership of 90,000 American Depository Shares in Chemomab Therapeutics Ltd., representing 1.2% of the class.
NASDAQ
Erik Otto has reported a 6.3% beneficial ownership stake in Chemomab Therapeutics Ltd., holding 385,000 American Depository Shares.
NASDAQ
SCHEDULE: Erik Otto Boosts Chemomab Stake to 8.1%
Erik Otto has increased his beneficial ownership in Chemomab Therapeutics Ltd. to 8.1% of the outstanding American Depository Shares.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported ceasing to be beneficial owners of more than five percent of Chemomab Therapeutics Ltd.'s ordinary shares.
NASDAQ
Morgan Stanley and its subsidiary have disclosed an 8.4% beneficial ownership stake in Chemomab Therapeutics Ltd. as of June 30, 2025.
NASDAQ
Sphera Funds Management and its affiliates have reported a beneficial ownership of 4.78% in Chemomab Therapeutics Ltd.'s American Depository Shares, marking a reduction below the 5% threshold.